甲泼尼龙与地塞米松治疗颅内肿瘤瘤周水肿的临床对照研究

目的 评价甲泼尼龙治疗颅内肿瘤瘤周水肿的临床疗效和安全性。方法 58例具有不同程度瘤周水肿的颅内肿瘤患者随机分为试验组和对照组，两组患者术前，术后分别静脉给予常规等效剂量甲泼尼龙和地塞米松治疗3－5d，观察两组患者在术前治疗过程中临床神经症状及体征的改善程度，在术前治疗前后作KPS评分，并观察两组患者在治疗过程中可能出现的副作用。结果 试验组30例中有19例的临床症状得到改善，有继63％，其中9例有明显改善，显效率为30％，对照组28例中有17例临床症状得到改善，有效率为60．7％，其中4例有明显疗效，显效率为14．3％。两组比较，有效率无明显差别，但显效率比较则有显著性差别（P＜0．05）。治疗期间，两组均无明显副作用发生。结论 甲泼尼龙可有效地减轻颅内肿瘤所致的瘤周水肿，且无明显副作用。

Clinical Control Trial of Methylprednisolone and Dexamethasone in Treatment of Intracranial Tumor Edema

Objective This study was designed to evaluate the therapentic effect and side effect of methylprednisolone on brain tumor edema. Methods Fifty eight patients with brain tumor edema revealed by CT/MRI were randomly divided into two groups. 30 patients of trial group were treated with methylprednisolone,and 28 patients of the control group received dexamethasone for 3 5 days before and after operation.The patients'clinical neurological symptoms and signs were observed at the beginning and end of treatment before operation, and Karnofsky Performance Scores, were given to the case. Furthermore, the patients' cell immunty, electrolytes, blood sugar that might be a ffected, by methylprednisolone and dexamethsone were investigated concerned. Results Ninteen of 30 patients taking methylprednisolone and seventeen of 28 patients taking dexamethasone showed improvement in their dinical neurological symptoms, total effective rates for methylprednisolone and dexamethasone groups were 63.0% and 60.7% respectiveiy. there was no obvious difference between the two groups in this regard rate ( P >0.05). Furthermore nine patients (30.0%) in trial group show signigicant improvement, whereas only four patients (14.3%) in the control group show significat improvment, the difference here was satatitically significant ( P <0.05). There was no obvious side effect in both groups during treatment. Conclusion Vasogenic edema associated with brain tumor and its induced symptoms was effectively treated by methylprednisolone without adverse effects, Current findings suggest that further study of methylprednisolone in the management of centrol nervous system tumors is warranted.